Adenoviral Conjunctivitis
Conditions
Brief summary
The purpose of this study is to determine if an investigational treatment is effective compared with placebo in the treatment of adults and children with adenoviral conjunctivitis.
Interventions
DRUGSHP640
Instill 1 drop of SHP640 (PVP-I 0.6% and Dexamethasone 0.1%) ophthalmic suspension in each eye 4 times daily (QID) (with a minimum of 2 hours between doses) for 7 days.
DRUGPlacebo
Instill 1 drop of placebo ophthalmic solution in each eye QID for 7 days.
Sponsors
Shire
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
1. An understanding, ability, and willingness to fully comply with study procedures and restrictions (by the parent(s), guardian, or legally authorized representative, if applicable). 2. Ability to voluntarily provide written, signed, and dated (personally or via a parent(s), guardian, or legally-authorized representative(s) informed consent (and assent, if applicable) to participate in the study. 3. Participants of any age at Visit 1 (Note: Participants less than (\<) 3 months of age at Visit 1 must have been full-term, that is greater than or equal to (\>=) 37 weeks gestational age at birth). 4. Meet at least 1 of the 2 criteria below: a. Have a positive AdenoPlus® test at Visit 1 in at least 1 eye; b. Have at least 2 of the following 5 criteria, based upon medical history and examination: i. Symptoms within the past 7 days consistent with acute upper respiratory tract infection (example: sore throat, cough, rhinorrhea, etc); ii. Contact within the past 7 days with family members or other individuals with recent onset of symptoms consistent with conjunctivitis; iii. Acute onset within the past 4 days of 1 or more of the following ocular symptoms: burning/irritation, foreign body sensation, light sensitivity; iv. Enlarged periauricular lymph node(s); v. Presence of follicles on tarsal conjunctiva. Note: If the participant only meets Inclusion Criterion 4a (a positive AdenoPlus test in at least 1 eye), then the same eye must meet Inclusion Criterion 5. 5. Have a clinical diagnosis of suspected adenoviral conjunctivitis in at least 1 eye confirmed by the presence of the following minimal clinical signs and symptoms in that same eye: Report presence of signs and/or symptoms of adenoviral conjunctivitis for less than or equal to (\<=) 4 days prior to Visit 1; Bulbar conjunctival injection: a grade of \>=1 on 0-4 scale of Bulbar Conjunctival Injection Scale; Watery conjunctival discharge: a grade of \>=1 (mild) on a 0-3 Watery Conjunctival Discharge Scale. 6. Be willing to discontinue contact lens wear for the duration of the study. 7. Have a Best Corrected Visual Acuity (BCVA) of 0.60 logMAR or better in each eye as measured using an Early Treatment Diabetic Retinopathy Study (ETDRS) chart. BCVA will be assessed by an age appropriate method in accordance with the American Academy of Pediatrics (AAP) Policy Statement for Visual System Assessment in Infants, Children, and Young Adults by Pediatricians. The policy statement recommends formal vision screening can begin at 3 years of age. VA measurements for children under the age of 3 will be done at the discretion of the investigator. If not done, child should be able to fixate on and follow a moving object, except participants \< 2 months of age who have not yet developed this ability. Participants \< 2 months will be enrolled at the discretion of the investigator. 8. Male, or non-pregnant, non-lactating female who agrees to comply with any applicable contraceptive requirements of the protocol or females of non-childbearing potential.
Exclusion criteria
1. Current or recurrent disease that could affect the action, absorption, or disposition of the investigational product, or clinical or laboratory assessments, per investigator's discretion. 2. Current or relevant history of physical or psychiatric illness, any medical disorder that may make the participant unlikely to fully complete the study, or any condition that presents undue risk from the investigational product or procedures. 3. Have known or suspected intolerance or hypersensitivity to the investigational product, closely related compounds, or any of the stated ingredients. 4. Prior enrollment in a FST-100 or SHP640 clinical study. 5. Participants who are employees, or immediate family members of employees (who are directly related to study conduct), at the investigational site. 6. Have a history of ocular surgical intervention within \<= 6 months prior to Visit 1 or planned for the period of the study. 7. Have a preplanned overnight hospitalization during the period of the study. 8. Have presence of any intraocular, corneal, or conjunctival ocular inflammation (example: uveitis, iritis, ulcerative keratitis, chronic blepharoconjunctivitis), other than adenoviral conjunctivitis. 9. Have presence of corneal subepithelial infiltrates at Visit 1. 10. Have active or history of ocular herpes. 11. Have at enrollment or within \<= 30 days of Visit 1, a clinical presentation more consistent with the diagnosis of non-infectious conjunctivitis (except presumed seasonal/perennial allergic conjunctivitis) or non-adenoviral ocular infection (example: bacterial, fungal, acanthamoebal, or other parasitic). Note: History or concomitant presence of presumed seasonal or perennial allergic conjunctivitis signs/symptoms is not exclusionary. 12. Neonates or infants (that is (ie,) participants \< 12 months of age) who have suspected or confirmed (based on the result of any test conducted prior to screening) conjunctivitis of gonococcal, chlamydial, herpetic or chemical origin. 13. Neonates or infants (ie, participants \< 12 months of age) whose birth mothers had any sexually transmitted disease within 1 month of delivery or any history of genital herpes. 14. Presence of nasolacrimal duct obstruction at Visit 1 (Day 1). 15. Presence of any significant ophthalmic condition (example: retinopathy of prematurity, congenital cataract, congenital glaucoma) or other congenital disorder with ophthalmic involvement that could affect study variables. 16. Be a known intraocular pressure (IOP) steroid responder, have a known history or current diagnosis of glaucoma, or be a glaucoma suspect. 17. Have any known clinically significant optic nerve defects. 18. Have a history of recurrent corneal erosion syndrome, either idiopathic or secondary to previous corneal trauma or dry eye syndrome; presence of corneal epithelial defect or any significant corneal opacity at Visit 1. 19. Presence of significant, active condition in the posterior segment which requires invasive treatment (example: intravitreal treatment with VEGF inhibitors or corticosteroids) and may progress during the study participation period. 20. Have used any topical ocular or systemic anti-virals or antibiotics within \<= 7 days of enrollment. 21. Have used any topical ocular NSAIDs within \<= 1 day of enrollment. 22. Have used any topical ophthalmic steroids in the last \<= 14 days. 23. Have used any systemic corticosteroid agents within \<= 14 days of Day 1. Stable (initiated \>= 30 days prior to enrollment) use of inhaled and nasal corticosteroids is allowed, given no anticipated change in dose for the duration of the study. Topical dermal steroids are allowed except in the peri-ocular area. 24. Have used non-corticosteroid immunosuppressive agents within \<= 14 days of Day 1. 25. Have used any topical ophthalmic products, including tear substitutes, and over-the-counter preparations such as lid scrubs, within 2 hours of Visit 1 and be unable to discontinue all topical ophthalmic products for the duration of the study. Use of hot or cold compresses is also not permitted during the study. 26. Have any significant ocular disease (example: Sjogren's syndrome) or any uncontrolled systemic disease or debilitating disease (example: cardiovascular disease, hypertension, sexually transmitted diseases/infections, diabetes or cystic fibrosis), that may affect the study parameters, per investigator's discretion. 27. Any known history of immunodeficiency disorder or known active conditions predisposing to immunodeficiency, such as human immunodeficiency virus, hepatitis B or C, evidence of active hepatitis A (antihepatitis A virus immunoglobulin M), or organ or bone marrow transplantation. 28. Within 30 days prior to the first dose of investigational product: Have used an investigational product or device, or Have been enrolled in a clinical study (including vaccine studies) that, in the investigator's opinion, may impact this Shire-sponsored study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants With Clinical Resolution on Day 6 | Day 6 | Clinical resolution of adenoviral conjunctivitis was defined as the absence (score = 0) of bulbar conjunctival injection and watery conjunctival discharge in the study eye. Bulbar conjunctival injection was assessed based on a 0 (Normal conjunctival vascular pattern)-4 (Markedly prominent, intense diffuse hyperemia) scale which used pictures from the validated bulbar redness (VBR) scale. Watery conjunctival discharge was assessed based on a 0-3 scale (0 - None and 3 - Severe: Abundant quantity of watery discharge observed in the lower conjunctival fornix and in the lower lid margin). The study eye was defined based on participants bulbar conjunctival redness and watery conjunctival discharge scores, as well as his/her cell culture-immunofluorescence assay (CC-IFA) results at baseline. Higher scores represented worse symptoms for both scales. Percentage of participants with clinical resolution on Day 6 was reported. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Absolute Change and Change From Baseline in Adenovirus Viral Titer on Day 6 and 8 | Day 6 and 8 | Adenovirus viral titer was assessed by quantitative polymerase chain reaction (qPCR) in the study eye. The study eye was defined based on participant's bulbar conjunctival redness and watery conjunctival discharge scores, as well as his/her CC-IFA results at baseline. |
| Percentage of Participants With Adenoviral Eradication on Day 3, 8 and 12/Early Termination (ET) | Day 3, 8 and 12/ET | Adenoviral eradication for the study eye was defined as negative CC-IFA in that eye. CC-IFA for each eye was conducted using conjunctival swab samples collected at each visit to determine the presence of adenovirus. The study eye was defined based on participant's bulbar conjunctival redness and watery conjunctival discharge scores, as well as his/her CC-IFA results at baseline. Percentage of participants with adenoviral eradication on Day 3, 8 and 12/ET was reported. |
| Percentage of Participants With Clinical Resolution on Day 3, 8 and 12/Early Termination (ET) | Day 3, 8 and 12/ET | Clinical resolution of adenoviral conjunctivitis was defined as the absence (score = 0) of bulbar conjunctival injection and watery conjunctival discharge in the study eye. Bulbar conjunctival injection was assessed based on a 0 (Normal conjunctival vascular pattern)-4 (Markedly prominent, intense diffuse hyperemia) scale which used pictures from the validated bulbar redness (VBR) scale. Watery conjunctival discharge was assessed based on a 0-3 scale (0 - None and 3 - Severe: Abundant quantity of watery discharge observed in the lower conjunctival fornix and in the lower lid margin). The study eye was defined based on participant's bulbar conjunctival redness and watery conjunctival discharge scores, as well as his/her cell culture-immunofluorescence assay (CC-IFA) results at baseline. Higher scores represented worse symptoms for both scales. Percentage of participants with clinical resolution on Day 3, 8 and 12/ET was reported. |
| Number of Participants With Individual Clinical Signs Score at Day 3, 6, 8 and 12/Early Termination (ET) | Day 3, 6, 8 and 12/ET | Individual clinical signs scores for bulbar conjunctival injection and watery conjunctival discharge in the study eye were reported. Bulbar conjunctival injection was assessed based on a 0 (Normal conjunctival vascular pattern)-4 (Markedly prominent, intense diffuse hyperemia) scale which used pictures from the validated bulbar redness (VBR) scale. Watery conjunctival discharge was assessed based on a 0-3 scale (0 - None and 3 - Severe: Abundant quantity of watery discharge observed in the lower conjunctival fornix and in the lower lid margin). Higher score represented worse symptoms for both scores. The study eye was defined based on participant's bulbar conjunctival redness and watery conjunctival discharge scores, as well as his/her CC-IFA results at baseline. |
| Number of Participants With Global Clinical Score at Day 3, 6, 8 and 12/Early Termination (ET) | Day 3, 6, 8 and 12/ET | Global clinical score was the sum of bulbar conjunctival injection and watery conjunctival discharge in the study eye. Score range from 0 to 7 and higher scores represented worse symptoms. The study eye was defined based on participant's bulbar conjunctival redness and watery conjunctival discharge scores, as well as his/her CC-IFA results at baseline. |
| Percentage of Participants With Adenoviral Eradication on Day 6 | Day 6 | Adenoviral eradication for the study eye was defined as negative CC-IFA in that eye. The CC-IFA for each eye was conducted using conjunctival swab samples collected at each visit to determine the presence of adenovirus. The study eye was defined based on participant's bulbar conjunctival redness and watery conjunctival discharge scores, as well as his/her CC-IFA results at baseline. Percentage of participants with adenoviral eradication on Day 6 was reported. |
| Percentage of Participants With Expanded Clinical Resolution at Day 3, 6, 8 and 12/Early Termination (ET) | Day 3, 6, 8 and 12/ET | Expanded clinical resolution was defined as a global clinical score of 0, 1, or 2 with neither injection nor discharge having a score of 2 in the study eye. Global clinical score was the sum of bulbar conjunctival injection and watery conjunctival discharge. Score range from 0 to 7 and higher scores represent worse symptoms. The study eye was defined based on participant's bulbar conjunctival redness and watery conjunctival discharge scores, as well as his/her CC-IFA results at baseline. |
| Percentage of Participants With Cross-Over Infection at Day 3, 6, 8 and 12/Early Termination (ET) | Day 3, 6, 8 and 12/ET | Cross-over infection to a participant's fellow eye for participants with only 1 infected eye at baseline was reported. The CC-IFA for each eye was conducted using conjunctival swab samples collected at each visit to determine the presence of adenovirus. |
| Time to Clinical Resolution on Day 3, 6, 8 and 12/Early Termination (ET) | Day 3, 6, 8 and 12/ET | Time to clinical resolution was reported based on the assessments in the study eye.The study eye was defined based on participant's bulbar conjunctival redness and watery conjunctival discharge scores, as well as his/her CC-IFA results at baseline. |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | From start of study drug administration up to Day 13 | An adverse event (AE) was any unfavorable and unintended sign, symptom, or disease temporally associated with the study or use of investigational drug product, whether or not the AE is considered related to the investigational drug product. Treatment-Emergent Adverse Events (TEAEs) were defined as those adverse events that occurred after the first dose of investigational product. |
| Percentage of Participants With Modified Clinical Resolution at Day 3, 6, 8 and 12/Early Termination (ET) | Day 3, 6, 8 and 12/ET | Modified clinical resolution was defined as a global clinical score of 0 or 1 in the study eye. Global clinical score was the sum of bulbar conjunctival injection and watery conjunctival discharge. Score range from 0 to 7 and higher scores represent worse symptoms.The study eye was defined based on participant's bulbar conjunctival redness and watery conjunctival discharge scores, as well as his/her CC-IFA results at baseline. |
Countries
Puerto Rico, United States
Participant flow
Recruitment details
The study was conducted at 30 centers in the United States and Puerto Rico between 28 March 2017 (first participant first visit) and 16 May 2019 (last participant last visit).
Pre-assignment details
A total of 156 participants were randomized and received the treatment. Out of them, 134 participants completed the study.
Participants by arm
| Arm | Count |
|---|---|
| SHP640 Participants administered one drop of SHP640 (Povidone-iodine \[PVP-I\] 0.6 percent \[%\] and Dexamethasone 0.1%) ophthalmic suspension in each eye 4 times daily (QID) for 7 days. | 79 |
| Placebo Participants administered one drop of placebo ophthalmic solution in each eye QID for 7 days. | 77 |
| Total | 156 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Adverse Event | 8 | 3 |
| Overall Study | Lack of Efficacy | 0 | 1 |
| Overall Study | Lost to Follow-up | 0 | 1 |
| Overall Study | Protocol deviation | 1 | 0 |
| Overall Study | Withdrawal by Subject | 2 | 6 |
Baseline characteristics
| Characteristic | SHP640 | Placebo | Total |
|---|---|---|---|
| Age, Continuous | 42.4 Years STANDARD_DEVIATION 21.57 | 41.3 Years STANDARD_DEVIATION 21.21 | 41.9 Years STANDARD_DEVIATION 21.33 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 10 Participants | 19 Participants | 29 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 68 Participants | 58 Participants | 126 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 1 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 1 Participants | 1 Participants |
| Race (NIH/OMB) Asian | 4 Participants | 0 Participants | 4 Participants |
| Race (NIH/OMB) Black or African American | 10 Participants | 8 Participants | 18 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 1 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) White | 64 Participants | 68 Participants | 132 Participants |
| Sex: Female, Male Female | 47 Participants | 53 Participants | 100 Participants |
| Sex: Female, Male Male | 32 Participants | 24 Participants | 56 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 79 | 0 / 77 |
| other Total, other adverse events | 20 / 79 | 8 / 77 |
| serious Total, serious adverse events | 0 / 79 | 0 / 77 |
Outcome results
Primary
Percentage of Participants With Clinical Resolution on Day 6
Clinical resolution of adenoviral conjunctivitis was defined as the absence (score = 0) of bulbar conjunctival injection and watery conjunctival discharge in the study eye. Bulbar conjunctival injection was assessed based on a 0 (Normal conjunctival vascular pattern)-4 (Markedly prominent, intense diffuse hyperemia) scale which used pictures from the validated bulbar redness (VBR) scale. Watery conjunctival discharge was assessed based on a 0-3 scale (0 - None and 3 - Severe: Abundant quantity of watery discharge observed in the lower conjunctival fornix and in the lower lid margin). The study eye was defined based on participants bulbar conjunctival redness and watery conjunctival discharge scores, as well as his/her cell culture-immunofluorescence assay (CC-IFA) results at baseline. Higher scores represented worse symptoms for both scales. Percentage of participants with clinical resolution on Day 6 was reported.
Time frame: Day 6
Population: Modified Intent to Treat (mITT) population consisted of a subset of the ITT Population who received at least one dose of investigational product and has a positive CC-IFA adenovirus test at baseline in the study eye. Here, the number of participants analyzed refer to the participants evaluable for this outcome.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| SHP640 | Percentage of Participants With Clinical Resolution on Day 6 | 11.1 Percentage of participants |
| Placebo | Percentage of Participants With Clinical Resolution on Day 6 | 20.0 Percentage of participants |
Secondary
Absolute Change and Change From Baseline in Adenovirus Viral Titer on Day 6 and 8
Adenovirus viral titer was assessed by quantitative polymerase chain reaction (qPCR) in the study eye. The study eye was defined based on participant's bulbar conjunctival redness and watery conjunctival discharge scores, as well as his/her CC-IFA results at baseline.
Time frame: Day 6 and 8
Population: The study was terminated as the sponsor discontinued the SHP640 clinical development with reason unrelated to safety. Hence, for this outcome measure, the planned data collection and analysis was not performed.
Secondary
Number of Participants With Global Clinical Score at Day 3, 6, 8 and 12/Early Termination (ET)
Global clinical score was the sum of bulbar conjunctival injection and watery conjunctival discharge in the study eye. Score range from 0 to 7 and higher scores represented worse symptoms. The study eye was defined based on participant's bulbar conjunctival redness and watery conjunctival discharge scores, as well as his/her CC-IFA results at baseline.
Time frame: Day 3, 6, 8 and 12/ET
Population: The study was terminated as the sponsor discontinued the SHP640 clinical development with reason unrelated to safety. Hence, for this outcome measure, the planned data collection and analysis was not performed.
Secondary
Number of Participants With Individual Clinical Signs Score at Day 3, 6, 8 and 12/Early Termination (ET)
Individual clinical signs scores for bulbar conjunctival injection and watery conjunctival discharge in the study eye were reported. Bulbar conjunctival injection was assessed based on a 0 (Normal conjunctival vascular pattern)-4 (Markedly prominent, intense diffuse hyperemia) scale which used pictures from the validated bulbar redness (VBR) scale. Watery conjunctival discharge was assessed based on a 0-3 scale (0 - None and 3 - Severe: Abundant quantity of watery discharge observed in the lower conjunctival fornix and in the lower lid margin). Higher score represented worse symptoms for both scores. The study eye was defined based on participant's bulbar conjunctival redness and watery conjunctival discharge scores, as well as his/her CC-IFA results at baseline.
Time frame: Day 3, 6, 8 and 12/ET
Population: The study was terminated as the sponsor discontinued the SHP640 clinical development with reason unrelated to safety. Hence, for this outcome measure, the planned data collection and analysis was not performed.
Secondary
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
An adverse event (AE) was any unfavorable and unintended sign, symptom, or disease temporally associated with the study or use of investigational drug product, whether or not the AE is considered related to the investigational drug product. Treatment-Emergent Adverse Events (TEAEs) were defined as those adverse events that occurred after the first dose of investigational product.
Time frame: From start of study drug administration up to Day 13
Population: Safety Population consisted of all screened participants who received at least one dose of investigational product.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| SHP640 | Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | 28 Participants |
| Placebo | Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | 17 Participants |
Secondary
Percentage of Participants With Adenoviral Eradication on Day 3, 8 and 12/Early Termination (ET)
Adenoviral eradication for the study eye was defined as negative CC-IFA in that eye. CC-IFA for each eye was conducted using conjunctival swab samples collected at each visit to determine the presence of adenovirus. The study eye was defined based on participant's bulbar conjunctival redness and watery conjunctival discharge scores, as well as his/her CC-IFA results at baseline. Percentage of participants with adenoviral eradication on Day 3, 8 and 12/ET was reported.
Time frame: Day 3, 8 and 12/ET
Population: mITT population consisted of a subset of the ITT Population who received at least one dose of investigational product and has a positive CC-IFA adenovirus test at baseline in the study eye. Here, the number of participants analyzed refer to the participants evaluable for this outcome at specific time point.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| SHP640 | Percentage of Participants With Adenoviral Eradication on Day 3, 8 and 12/Early Termination (ET) | Day 3 | 11.1 Percentage of participants |
| SHP640 | Percentage of Participants With Adenoviral Eradication on Day 3, 8 and 12/Early Termination (ET) | Day 8 | 71.4 Percentage of participants |
| SHP640 | Percentage of Participants With Adenoviral Eradication on Day 3, 8 and 12/Early Termination (ET) | Day 12/ET | 77.8 Percentage of participants |
| Placebo | Percentage of Participants With Adenoviral Eradication on Day 3, 8 and 12/Early Termination (ET) | Day 3 | 16.7 Percentage of participants |
| Placebo | Percentage of Participants With Adenoviral Eradication on Day 3, 8 and 12/Early Termination (ET) | Day 8 | 66.7 Percentage of participants |
| Placebo | Percentage of Participants With Adenoviral Eradication on Day 3, 8 and 12/Early Termination (ET) | Day 12/ET | 100 Percentage of participants |
Secondary
Percentage of Participants With Adenoviral Eradication on Day 6
Adenoviral eradication for the study eye was defined as negative CC-IFA in that eye. The CC-IFA for each eye was conducted using conjunctival swab samples collected at each visit to determine the presence of adenovirus. The study eye was defined based on participant's bulbar conjunctival redness and watery conjunctival discharge scores, as well as his/her CC-IFA results at baseline. Percentage of participants with adenoviral eradication on Day 6 was reported.
Time frame: Day 6
Population: mITT population consisted of a subset of the ITT Population who received at least one dose of investigational product and has a positive CC-IFA adenovirus test at baseline in the study eye. Here, the number of participants analyzed refer to the participants evaluable for this outcome.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| SHP640 | Percentage of Participants With Adenoviral Eradication on Day 6 | 33.3 Percentage of participants |
| Placebo | Percentage of Participants With Adenoviral Eradication on Day 6 | 70.0 Percentage of participants |
Secondary
Percentage of Participants With Clinical Resolution on Day 3, 8 and 12/Early Termination (ET)
Clinical resolution of adenoviral conjunctivitis was defined as the absence (score = 0) of bulbar conjunctival injection and watery conjunctival discharge in the study eye. Bulbar conjunctival injection was assessed based on a 0 (Normal conjunctival vascular pattern)-4 (Markedly prominent, intense diffuse hyperemia) scale which used pictures from the validated bulbar redness (VBR) scale. Watery conjunctival discharge was assessed based on a 0-3 scale (0 - None and 3 - Severe: Abundant quantity of watery discharge observed in the lower conjunctival fornix and in the lower lid margin). The study eye was defined based on participant's bulbar conjunctival redness and watery conjunctival discharge scores, as well as his/her cell culture-immunofluorescence assay (CC-IFA) results at baseline. Higher scores represented worse symptoms for both scales. Percentage of participants with clinical resolution on Day 3, 8 and 12/ET was reported.
Time frame: Day 3, 8 and 12/ET
Population: mITT population consisted of a subset of the ITT Population who received at least one dose of investigational product and has a positive CC-IFA adenovirus test at baseline in the study eye. Here, the number of participants analyzed refer to the participants evaluable for this outcome at specific time point.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| SHP640 | Percentage of Participants With Clinical Resolution on Day 3, 8 and 12/Early Termination (ET) | Day 3 | 11.1 Percentage of participants |
| SHP640 | Percentage of Participants With Clinical Resolution on Day 3, 8 and 12/Early Termination (ET) | Day 8 | 14.3 Percentage of participants |
| SHP640 | Percentage of Participants With Clinical Resolution on Day 3, 8 and 12/Early Termination (ET) | Day 12/ET | 33.3 Percentage of participants |
| Placebo | Percentage of Participants With Clinical Resolution on Day 3, 8 and 12/Early Termination (ET) | Day 8 | 44.4 Percentage of participants |
| Placebo | Percentage of Participants With Clinical Resolution on Day 3, 8 and 12/Early Termination (ET) | Day 3 | 0 Percentage of participants |
| Placebo | Percentage of Participants With Clinical Resolution on Day 3, 8 and 12/Early Termination (ET) | Day 12/ET | 50.0 Percentage of participants |
Secondary
Percentage of Participants With Cross-Over Infection at Day 3, 6, 8 and 12/Early Termination (ET)
Cross-over infection to a participant's fellow eye for participants with only 1 infected eye at baseline was reported. The CC-IFA for each eye was conducted using conjunctival swab samples collected at each visit to determine the presence of adenovirus.
Time frame: Day 3, 6, 8 and 12/ET
Population: The study was terminated as the sponsor discontinued the SHP640 clinical development with reason unrelated to safety. Hence, for this outcome measure, the planned data collection and analysis was not performed.
Secondary
Percentage of Participants With Expanded Clinical Resolution at Day 3, 6, 8 and 12/Early Termination (ET)
Expanded clinical resolution was defined as a global clinical score of 0, 1, or 2 with neither injection nor discharge having a score of 2 in the study eye. Global clinical score was the sum of bulbar conjunctival injection and watery conjunctival discharge. Score range from 0 to 7 and higher scores represent worse symptoms. The study eye was defined based on participant's bulbar conjunctival redness and watery conjunctival discharge scores, as well as his/her CC-IFA results at baseline.
Time frame: Day 3, 6, 8 and 12/ET
Population: The study was terminated as the sponsor discontinued the SHP640 clinical development with reason unrelated to safety. Hence, for this outcome measure, the planned data collection and analysis was not performed.
Secondary
Percentage of Participants With Modified Clinical Resolution at Day 3, 6, 8 and 12/Early Termination (ET)
Modified clinical resolution was defined as a global clinical score of 0 or 1 in the study eye. Global clinical score was the sum of bulbar conjunctival injection and watery conjunctival discharge. Score range from 0 to 7 and higher scores represent worse symptoms.The study eye was defined based on participant's bulbar conjunctival redness and watery conjunctival discharge scores, as well as his/her CC-IFA results at baseline.
Time frame: Day 3, 6, 8 and 12/ET
Population: The study was terminated as the sponsor discontinued the SHP640 clinical development with reason unrelated to safety. Hence, for this outcome measure, the planned data collection and analysis was not performed.
Secondary
Time to Clinical Resolution on Day 3, 6, 8 and 12/Early Termination (ET)
Time to clinical resolution was reported based on the assessments in the study eye.The study eye was defined based on participant's bulbar conjunctival redness and watery conjunctival discharge scores, as well as his/her CC-IFA results at baseline.
Time frame: Day 3, 6, 8 and 12/ET
Population: The study was terminated as the sponsor discontinued the SHP640 clinical development with reason unrelated to safety. Hence, for this outcome measure, the planned data collection and analysis was not performed.